MORPHEUS-Liver provides a way forward in expanding the immunotherapy options for hepatocellular carcinoma

IF 82.2 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-03-10 DOI:10.1038/s41571-025-01009-x

Bruno Sangro, Josepmaria Argemí

引用次数: 0

Abstract

Advanced-stage hepatocellular carcinoma is currently treated with various anti-PD-(L)1 antibody-containing regimens. Now, a triplet combining the anti-TIGIT antibody tiragolumab with one of these regimens has demonstrated promising efficacy in a phase Ib/II trial, although these data will need to be confirmed. This study highlights the value of umbrella trials while also raising questions regarding the most effective immune-targeting strategies in patients with this disease.

查看原文本刊更多论文

MORPHEUS-Liver为扩大肝细胞癌的免疫治疗选择提供了一条前进的道路

晚期肝细胞癌目前用各种含抗pd -(L)1抗体的方案治疗。现在，抗tigit抗体tiragolumab与其中一种方案的三联用药在Ib/II期试验中显示出有希望的疗效，尽管这些数据还需要进一步证实。这项研究强调了保护伞试验的价值，同时也提出了关于这种疾病患者最有效的免疫靶向策略的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.